Cargando…

Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

BACKGROUND: Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xiuting, Cheng, Wei, Fan, Shengxian, Huang, Yuhua, Chen, Xi, Jiang, Zhiwei, Wang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207711/ https://www.ncbi.nlm.nih.gov/pubmed/34134659 http://dx.doi.org/10.1186/s12879-021-06270-w

Ejemplares similares

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure
por: Pizzoferrato, Marco, et al.
Publicado: (2022)

Intestinal dysbiosis in children with short bowel syndrome is associated with impaired outcome
por: Engstrand Lilja, Helene, et al.
Publicado: (2015)

Regulation of glucagon‐like peptide‐1 sensitivity by gut microbiota dysbiosis
por: Yamane, Shunsuke, et al.
Publicado: (2017)

An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults
por: Zhu, Changzhen, et al.
Publicado: (2022)

Dysbiosis of Fungal Microbiota in the Intestinal Mucosa of Patients with Colorectal Adenomas
por: Luan, Chunguang, et al.
Publicado: (2015)

Effects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in rats
por: Lai, Sarah W., et al.
Publicado: (2017)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function
por: Jeppesen, P. B., et al.
Publicado: (2009)

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
por: Jeppesen, P. B., et al.
Publicado: (2009)

Fungal Dysbiosis and Intestinal Inflammation in Children With Beta-Cell Autoimmunity
por: Honkanen, Jarno, et al.
Publicado: (2020)

Effects of glepaglutide, a long‐acting glucagon‐like peptide‐2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial
por: Naimi, Rahim M., et al.
Publicado: (2022)

Effect of Aging and Glucagon-like Peptide 2 on Intestinal Microbiota in SD Rats
por: Wu, Jiayu, et al.
Publicado: (2018)

A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor
por: Sun, Wen, et al.
Publicado: (2020)

Acylation of Glucagon-Like Peptide-2: Interaction with Lipid Membranes and In Vitro Intestinal Permeability
por: Trier, Sofie, et al.
Publicado: (2014)

Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport
por: Lee, Jennifer, et al.
Publicado: (2017)

Apraglutide, a novel glucagon‐like peptide‐2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo‐controlled, randomized phase 2 trial
por: Eliasson, Johanna, et al.
Publicado: (2021)

Fungal dysbiosis facilitates inflammatory bowel disease by enhancing CD4+ T cell glutaminolysis
por: Yu, Minhao, et al.
Publicado: (2023)

Fungal microbiota dysbiosis in IBD
por: Sokol, Harry, et al.
Publicado: (2017)

Microbiota Dysbiosis in Fungal Rhinosinusitis
por: Lu, Yen-Ting, et al.
Publicado: (2019)

Apraglutide, a novel once‐weekly glucagon‐like peptide‐2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open‐label phase 1 and 2 metabolic balance trial
por: Eliasson, Johanna, et al.
Publicado: (2022)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials
por: Seidner, Douglas L, et al.
Publicado: (2015)

Glucagon-Like Peptide-2 Stimulates S-Phase Entry of Intestinal Lgr5+ Stem Cells
por: Chen, Maegan E., et al.
Publicado: (2022)

Interplay between Serotonin, Immune Response, and Intestinal Dysbiosis in Inflammatory Bowel Disease
por: González Delgado, Samantha, et al.
Publicado: (2022)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Salivary Hormones Leptin, Ghrelin, Glucagon, and Glucagon-Like Peptide 1 and Their Relation to Sweet Taste Perception in Diabetic Patients
por: Al-Ghurayr, Nada K., et al.
Publicado: (2023)

Chicken Intestinal L Cells and Glucagon-like Peptide-1 Secretion
por: Hiramatsu, Kohzy
Publicado: (2020)

Neonatal intestinal dysbiosis
por: Underwood, Mark A., et al.
Publicado: (2020)

The prolonged effect of glucagon-like peptide 2 pretreatment on growth performance and intestinal development of weaned piglets
por: Deng, Qiu Hong, et al.
Publicado: (2016)

Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice
por: Hytting-Andreasen, Rasmus, et al.
Publicado: (2018)

Antibiotic-driven intestinal dysbiosis in pediatric short bowel syndrome is associated with persistently altered microbiome functions and gut-derived bloodstream infections
por: Thänert, Robert, et al.
Publicado: (2021)

The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant?
por: Trapp, Stefan, et al.
Publicado: (2013)

Biotin Deficiency Induces Intestinal Dysbiosis Associated with an Inflammatory Bowel Disease-like Phenotype
por: Yang, Julianne C., et al.
Publicado: (2023)

Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease
por: Lemons, Johanna M.S., et al.
Publicado: (2023)

Elevations in growth hormone and glucagon-like peptide-2 levels on admission are associated with increased mortality in trauma patients
por: Rowan, Matthew P., et al.
Publicado: (2016)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Distribution of Glucagon-Like Peptide (GLP)-2-Immunoreactive Cells in the Chicken Small Intestine: Antigen Retrieval Immunohistochemistry
por: MONIR, Mohammad M., et al.
Publicado: (2013)

Ultrastructural Study on Colocalization of Glucagon-Like Peptide (GLP)-1 with GLP-2 in Chicken Intestinal L-Cells
por: NISHIMURA, Kei, et al.
Publicado: (2013)

Generation of glucagon‐like peptide‐2‐expressing Saccharomyces cerevisiae and its improvement of the intestinal health of weaned rats
por: Zhang, Zhongwei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_efhm0jfcd833ebsnnfs34u7u8l